Roux-en-Y gastric bypass (RYGB) is linked to greater weight loss compared to two other bariatric procedures but also the highest risk of adverse events in the short term, researchers reported in the Annals of Internal Medicine.

Cannabis use is associated with double the risk of diabetic ketoacidosis among patients with type 1 diabetes, according to a research letter published Nov. 5 in JAMA Internal Medicine.

A 13-year study of type 2 diabetes patients has found metformin, one of the world’s highest-grossing anti-diabetic medications, could be protective against age-related macular degeneration, a leading cause of blindness in Americans older than 50.

Low-risk patients with mild hypertension derived no protective benefit from blood pressure drugs over 5.8 years of follow-up but had an increased risk of adverse effects potentially related to the medication, researchers reported in a new study.

With the American Heart Association’s 2018 Scientific Sessions set for Nov. 10-12 in Chicago, two co-chairs of the programming committee previewed the themes of the meeting, its most anticipated clinical trials and the two new guidelines that will be unveiled.

ScieGen Pharmaceuticals has issued a recall of the blood pressure drug irbesartan after lab testing revealed a carcinogenic impurity, the FDA announced in a MedWatch Safety Alert.

A study out of Binghamton University in New York suggests heart rate (HR) and blood pressure (BP) respond to environmental demands by undergoing allostasis rather than homeostasis, adding further evidence to a hypothesis scientists have mulled for years.

Another drug with the potential to lower cholesterol beyond maximally tolerated statin therapy is preparing to enter the marketplace, STAT reported on Oct. 28.